Research programme: gamma delta T-cell immunotherapy - Gadeta

Drug Profile

Research programme: gamma delta T-cell immunotherapy - Gadeta

Alternative Names: TEG 001

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University Medical Center Utrecht
  • Developer Gadeta
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 19 Jul 2018 Kite Pharma and Gadeta entered into a strategic collaboration to develop gamma delta TCR therapies for the treatment Cancer
  • 25 Jul 2017 Gadeta plans a phase I trial of TEG 001 for Acute myeloid leukaemia, Multiple myeloma, Myelodysplastic syndrome (Second-line therapy or greater) in the Netherlands (NTR6541)
  • 29 Mar 2016 Early research in Cancer in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top